Pharmacogenetics of Parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: Differences in association with dopamine and serotonin receptors

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 147, Issue 6, 2008, Pages 890-897

  Al Hadithy, Asmar F ^a,b,c   Wilffert, Bob ^a,b   Stewart, Roy E ^c   Looman, Nicole M ^a   Bruggeman, Richard ^a,c   Brouwers, Jacobus R ^a,b   Matroos, Glenn E ^d   Van Os, Jim ^e   Hoek, Hans W ^c,f   Van Harten, Peter N ^c,g  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Zorggroep Noorderbreedte and de Tjongerschans ^*  (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d Dr DR Capriles Clinic   (Netherlands)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f PARNASSIA PSYCHIATRIC INSTITUTE   (Netherlands)

^g Psychiatric Centre Symfora Group   (Netherlands)

Author keywords

Antipsychotics; Bradykinesia; Parkinsonism; Rigidity; Tremor

Indexed keywords

BENZATROPINE; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN RECEPTOR;

ADULT; AFRICAN CARIBBEAN; ALLELE; ANTIPSYCHOTIC INDUCED PARKINSONISM; ARTICLE; BRADYKINESIA; CHI SQUARE TEST; CLINICAL FEATURE; DEMENTIA; DRD3 GENE; FEMALE; FISHER EXACT TEST; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HOSPITAL PATIENT; HTR2A GENE; HTR2C GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOOD DISORDER; NEUROLOGIC DISEASE; PARKINSONISM; PHARMACOGENETICS; PRIORITY JOURNAL; RIGIDITY; RISK FACTOR; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHOLINERGIC ANTAGONISTS; DRUG RESISTANCE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; HYPOKINESIA; INPATIENTS; MALE; MIDDLE AGED; MUSCLE RIGIDITY; PARKINSONIAN DISORDERS; PHARMACOGENETICS; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; TREMOR; WEST INDIES;

EID: 51449106702     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30746     Document Type: Article

References (66)

1. Alex KD, Yavanian GJ, McFarlane HG, Pluto CP, Pehek EA. 2005. Modulation of dopamine release by striatal 5-HT2C receptors. Synapse 55:242-251.
2. Arinami T, Gao M, Hamaguchi H, Toru M. 1997. Afunctional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 6:577-582.
3. Armstrong M, Daly AK, Blennerhassett R, Ferrier N, Idle JR. 1997. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry 170:23-26. 23-26.
4. Bakker PR, van Harten PN, van Os J. 2006. Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: A meta analysis. Schizophr Res 83:185-192.
5. Bejjani B, Damier P, Arnulf I, Bonnet AM, Vidailhet M, Dormont D, Pidoux B, Cornu P, Marsault C, Agid Y. 1997. Pallidal stimulation for Parkinson's disease. Two targets? Neurology 49:1564-1569.
6. Caligiuri MP, Lacro JP, Jeste DV. 1999. Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J Clin Psychopharmacol 19:322-328.
7. Caligiuri MR, Jeste DV, Lacro JP. 2000. Antipsychotic-induced movement disorders in the elderly: Epidemiology and treatment recommendations. Drugs Aging 17:363-384.
8. Chong SA, Tan EC, Tan CH, Mythily Chan YH. 2003. Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia. Am J Med Genet Part B 116:51-54.
9. Davis JM. 1976. Comparative doses and costs of antipsychotic medication. Arch Gen Psychiatry 33:858-861.
10. Di GG, Di MV, Pierucci M, Benigno A, Esposito E. 2006. Serotonin involvement in the basal ganglia pathophysiology: Could the 5-HT2C receptor be a new target for therapeutic strategies? Curr Med Chem 13:3069-3081.
11. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, Gejman PV. 2003. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12:205-216.
12. Ebadi M, Srinivasan SK. 1995. Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders. Pharmacol Rev 47:575-604.
13. Ebstein RP, Segman R, Benjamin J, Osher Y, Nemanov L, Belmaker RH. 1997. 5-HT2C (HTR2C) serotonin receptor gene polymorphism associated with the human personality trait of reward dependence: Interaction with dopamine D4 receptor (D4DR) and dopamine D3 receptor (D3DR) polymorphisms. Am J Med Genet 74:65-72.
14. Eichhammer P, Albus M, Borrmann-Hassenbach M, Schoeler A, Putzhammer A, Frick U, Klein HE, Rohrmeier T. 2000. Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: A generalization of Steen's study on DRD3 and tardive dyskinesia. Am J Med Genet 96:187-191.
15. Fentress HM, Grinde E, Mazurkiewicz JE, Backstrom JR, Herrick-Davis K, Sanders-Bush E. 2005. Pharmacological properties of the Cys23Ser single nucleotide polymorphism in human 5-HT2C receptor isoforms. Pharmacogenomics J 5:244-254.
16. Fleischhacker WW, Meise U, Gunther V, Kurz M. 1994. Compliance with antipsychotic drug treatment: Influence of side effects. Acta Psychiatr Scand Suppl 382:11-15.
17. Galdi J, Rieder RO, Silber D, Bonato RR. 1981. Genetic factors in the response to neuroleptics in schizophrenia: A psychopharmacogenetic study. Psychol Med 11:713-728.
18. Gerlach J. 1999. The continuing problem of extrapyramidal symptoms: Strategies for avoidance and effective treatment. J Clin Psychiatry 60(Suppl 23):20-24.
19. Gross RE, Lombardi WJ, Lang AE, Duff J, Hutchison WD, Saint-Cyr JA, Tasker RR, Lozano AM. 1999. Relationship of lesion location to clinical outcome following microelectrode-guided pallidotomy for Parkinson's disease. Brain 122:405-416.
20. Gunes A, Scordo MG, Jaanson P, Dahl ML. 2007. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psychopharmacology (Berl) 190:479-484.
21. Guzey C, Scordo MG, Spina E, Landsem VM, Spigset O. 2007. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: Associations with dopamine and serotonin receptor and transporter polymorphisms. Eur J Clin Pharmacol 63:233-241.
22. Haleem DJ. 2006. Serotonergic modulation of dopamine neurotransmission: A mechanism for enhancing therapeutics in schizophrenia. J Coll Physicians Surg Pak 16:556-562.
23. Hamdani N, Bonniere M, Ades J, Hamon M, Boni C, Gorwood P. 2005. Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics. Neurosci Lett 377:69-74.
24. Hassin-Baer S, Sirota P, Korczyn AD, Treves TA, Epstein B, Shabtai H, Martin T, Litvinjuk Y, Giladi N. 2001. Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm 108:1299-1308.
25. Hausner RS. 1983. Neuroleptic-induced parkinsonism and Parkinson's disease: Differential diagnosis and treatment. J Clin Psychiatry 44:13-16.
26. Hirose G. 2006. Drug induced parkinsonism: A review. J Neurol 253 (Suppl 3):22-24.
27. Hirvonen M, Laakso A, Nagren K, Rinne JO, Pohjalainen T, Hietala J. 2004. C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Mol Psychiatry 9:1060-1061.
28. Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW. 2004. Quality of life in schizophrenia: The impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry 65:932-939.
29. Inada T, Arinami T, Yagi G. 1999. Association between a polymorphism in the promoter region of the dopamine D2 receptor gene and schizophrenia in Japanese subjects: Replication and evaluation for antipsychotic-related features. Int J Neuropsychopharmcol 2:181-186.
30. Jabs BE, Bartsch AJ, Pfuhlmann B. 2003. Susceptibility to neuroleptic-induced parkinsonism-age and increased substantia nigra echogenicity as putative risk factors. Eur Psychiatry 18:177-181.
31. Jamora D, Lim SH, Pan A, Tan L, Tan EK. 2007. Valproate-induced Parkinsonism in epilepsy patients. Mov Disord 22:130-133.
32. Jonsson EG, Nothen MM, Grunhage F, Farde L, Nakashima Y, Propping P, Sedvall GC. 1999. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 4:290-296.
33. Jonsson EG, Bah J, Melke J, Abou JR, Schumacher J, Westberg L, Ivo R, Cichon S, Propping P, Nothen MM, Eriksson E, Sedvall GC. 2004. Monoamine related functional gene variants and relationships to monoamine metabolite concentrations in CSF of healthy volunteers. BMC Psychiatry 4:4.
34. Kaiser R, Tremblay PB, Klufmoller F, Roots I, Brockmoller J. 2002. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. Mol Psychiatry 7:695-705.
35. Koller WC. 1992. Initiating treatment of Parkinson's disease. Neurology 42:33-38.
36. Krack P, Pollak P, Limousin P, Hoffmann D, Benazzouz A, Le Bas JF, Koudsie A, Benabid AL. 1998. Opposite motor effects of pallidal stimulation in Parkinson's disease. Ann Neurol 43:180-192.
37. Lannfelt L, Sokoloff P, Martres MP, Pilon C, Giros B, Jonsson E, Sedvall G, Schwartz JC, Berger R. 1992. Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr Genet 2:249-256.
38. Lencer R, Eismann G, Kasten M, Kabakci K, Geithe V, Grimm J, Klein C. 2004. Family history of primary movement disorders as a predictor for neuroleptic-induced extrapyramidal symptoms. Br J Psychiatry 185:465-471.
39. Lera G, Zirulnik J. 1999. Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism. Mov Disord 14:128-131.
40. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R, Aschauer HN, McCreadie RG, Ohlraun S, Ferrier N, Masellis M, Verga M, Scharfetter J, Rietschel M, Lovlie R, Levy UH, Meltzer HY, Kennedy JL, Steen VM, Macciardi F. 2002. Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 27:105-119.
41. Lerer B, Segman RH, Tan EC, Basile VS, Cavallaro R, Aschauer HN, Strous R, Chong SA, Heresco-Levy U, Verga M, Scharfetter J, Meltzer HY, Kennedy JL, Macciardi F. 2005. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 8:411-425.
42. Lidow MS. 2000. Neurotransmitter receptors in actions of antipsychotic medications. Florida: CRC Press LLC. p 256.
43. Loonen AJ, van Praag HM. 2007. Measuring movement disorders in antipsychotic drug trials: The need to define a new standard. J Clin Psychopharmacol 27:423-430.
44. Martinez-Martin P, Gil-Nagel A, Gracia LM, Gomez JB, Martinez-Sarries J, Bermejo F. 1994. Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord 9:76-83.
45. Metzer WS, Newton JE, Steele RW, Claybrook M, Paige SR, McMillan DE, Hays S. 1989. HLA antigens in drug-induced parkinsonism. Mov Disord 4:121-128.
46. Mihara K, Suzuki A, Kondo T, Nagashima U, Ono S, Otani K, Kaneko S. 2000. No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: A preliminary study. Am J Med Genet 96:422-424.
47. Mihara K, Kondo T, Suzuki A, Yasui N, Ono S, Otani K, Kaneko S. 2001. No relationship between -141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: A preliminary study. Psychiatry Res 101:33-38.
48. Miller SA, Dykes DD, Polesky HF. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215.
49. Moleman P. 1992. Praktische psychofarmacologie. Houten: Bohn Stafleu Van Loghum. p 264.
50. Nakazono Y, Abe H, Murakami H, Koyabu N, Isaka Y, Nemoto Y, Murata S, Tsutsumi Y, Ohtani H, Sawada Y. 2005. Association between neuroleptic drug-induced extrapyramidal symptoms and dopamine D2-receptor polymorphisms in Japanese schizophrenic patients. Int J Clin Pharmacol Ther 43:163-171.
51. Ohashi J, Tokunaga K. 1999. Selecting a contingency table in a population-based association study: Allele frequency or positivity? J Hum Genet 44:246-248.
52. Ohashi J, Yamamoto S, Tsuchiya N, Hatta Y, Komata T, Matsushita M, Tokunaga K. 2001. Comparison of statistical power between 2 x 2 allele frequency and allele positivity tables in case-control studies of complex disease genes. Ann Hum Genet 65:197-206.
53. Okada M, Northup JK, Ozaki N, Russell JT, Linnoila M, Goldman D. 2004. Modification of human 5-HT(2C) receptor function by Cys23Ser, an abundant, naturally occurring amino-acid substitution. Mol Psychiatry 9:55-64.
54. Page WF. 1997. The Dutch Triangle: The Netherlands and the Atlantic Slave Trade,1621-1664. New York: Garland. p 262.
55. Pohjalainen T, Nagren K, Syvalahti EK, Hietala J. 1999. The dopamine D2 receptor 5′-flanking variant, -141C Ins/Del, is not associated with reduced dopamine D2 receptor density in vivo. Pharmacogenetics 9:505-509.
56. Reynolds GP. 2004. Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol 18:340-345.
57. Ritchie T, Noble EP. 2003. Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res 28:73-82.
58. Segman RH, Heresco-Levy U, Finkel B, Inbar R, Neeman T, Schlafman M, Dorevitch A, Yakir A, Lerner A, Goltser T, Shelevoy A, Lerer B. 2000. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: Additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl) 152:408-413.
59. Siemers E. 1992. Recent progress in the treatment of Parkinson's disease. Compr Ther 18:20-24.
60. Trosch RM. 2004. Neuroleptic-induced movement disorders: Deconstructing extrapyramidal symptoms. J Am Geriatr Soc 52:S266-S271.
61. van Harten PN, Matroos GE, Hoek HW, Kahn RS. 1996. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curacao Extrapyramidal Syndromes Study: I. Schizophr Res 19:195-203.
62. van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS. 1997. The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia: The Curacao Extrapyramidal Syndromes Study II. Schizophr Res 26:235-242.
63. van Harten PN, Hoek HW, Matroos GE, van OJ. 2006. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: The Curacao extrapyramidal syndromes study V. J Clin Psychiatry 67:1920-1927.
64. Warren JT Jr, Peacock ML, Rodriguez LC, Fink JK. 1993. An MspI polymorphism in the hyman serotonin receptor gene (HTR2): Detection by DGGE and RFLP analysis. Hum Mol Genet 2:338.
65. Wu SN, Gao R, Xing QH, Li HF, Shen YF, Gu NF, Feng GY, He L. 2006. Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sin 27:966-970.
66. Xu K, Lichtermann D, Lipsky RH, Franke P, Liu X, Hu Y, Cao L, Schwab SG, Wildenauer DB, Bau CH, Ferro E, Astor W, Finch T, Terry J, Taubman J, Maier W, Goldman D. 2004. Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations. Arch Gen Psychiatry 61:597-606.